Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808.
Aggregates of hyperphosphorylated tau (PHF-tau), such as neurofibrillary tangles, are linked to the degree of cognitive impairment in Alzheimer's disease. We have recently reported early clinical results of a novel PHF-tau targeting PET imaging agent, [F18]-T807. Since then, we have investigated a second novel PHF-tau targeting PET imaging agent, [F18]-T808, with different pharmacokinetic characteristics, which may be favorable for imaging Alzheimer's disease and other tauopathies. Here, we describe the first human brain images with [F18]-T808.
Siemens Molecular Imaging, Inc., Culver City, CA, USA.
David T
DT
Chien
A Katrin
AK
Szardenings
Shadfar
S
Bahri
Joseph C
JC
Walsh
Fanrong
F
Mu
Chunfang
C
Xia
William R
WR
Shankle
Alan J
AJ
Lerner
Min-Ying
MY
Su
Arkadij
A
Elizarov
Hartmuth C
HC
Kolb
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging*; D001562:Benzimidazoles / Q000493:pharmacokinetics; D001921:Brain / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism*; D001931:Brain Mapping; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008609:Mental Status Schedule; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011743:Pyrimidines / Q000493:pharmacokinetics; D013997:Time Factors; D016875:tau Proteins / Q000378:metabolism*
D001562:Benzimidazoles; D011743:Pyrimidines; C000588468:T808 compound; D016875:tau Proteins; D019788:Fluorodeoxyglucose F18
Alzheimer's disease; PHF-tau; amyloid-β; brain imaging; mild cognitive impairment; molecular imaging; neurofibrillary tangles; tau; tau aggregates; tauopathy